Encouraging updated interim Ph 2 data from GRANITE trial in 1L MSS-CRC announced

“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at study baseline,” said Andrew Allen, MD, PhD, Co-founder, President & CEO of Gritstone bio. “The powerful anti-tumor immunity induced by GRANITE in an immunologically cold tumor setting like MSS-CRC underscores a differentiated approach with a multitude of expansion opportunities across solid tumor indications. Moreover, these data also further de-risk SLATE, our off-the-shelf cancer immunotherapy program, and more importantly, reinforce the transformative potential of Gritstone’s overall immunotherapy platform.”